Global Mebendazole Market Size To Worth USD 401.66 Million by 2033 | CAGR of 5.01%
Category: HealthcareGlobal Mebendazole Market Size To Worth USD 401.66 Million by 2033
According to a research report published by Spherical Insights & Consulting, The Global Mebendazole Market Size is expected to Grow from USD 246.27 Million in 2023 to USD 401.66 Million by 2033, at a CAGR of 5.01% during the forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 204 pages with 100 Market data tables and figures & charts from the report on the "Global Mebendazole Market Size, Share, and COVID-19 Impact Analysis, By Dosage Form (Chewable Tablets, Oral Suspension, and Tablets), By Applications (Adult and Children), By Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/mebendazole-market
The mebendazole market is a crucial area of healthcare, focusing on the development, production, and distribution of anti-parasitic drugs for treating worm infestations like roundworm, hookworm, and whipworm. Mebendazole, a benzimidazole anthelmintic, is used to prevent worms from absorbing sugar, leading to their loss of energy and death. It inhibits microtubule production by binding to the colchicine binding site of β-tubulin, disrupting glucose uptake and parasites' digestive and reproductive capacities. Mebendazole is FDA-approved and has a good safety profile for human use. Government initiatives, such as the National Deworming Day in India, are driving market growth. The rising prevalence of helminthiasis has accelerated the need for anthelminthic drugs like mebendazole, particularly in developing regions with high poverty rates. The market is expected to grow further due to advancements in pharmaceutical formulations and the development of combination therapies. Chewable tablets and oral suspensions facilitate easier administration for children and elderly patients, and therapies that combine mebendazole with other treatments show greater efficacy in eradicating a wider variety of parasitic infections. However, the stringent regulatory framework may limit market growth.
The tablets segment held the largest share of 74.82% in 2023 and is predicted to grow at a significant CAGR during the predicted period.
Based on the dosage form, the global mebendazole market is categorized as chewable tablets, oral suspension, and tablets. Among these, the tablets segment held the largest share of 74.82% in 2023 and is predicted to grow at a significant CAGR during the predicted period. This is driven by administration ease, longer shelf life, patient convenience, stability, precise dosing, cost-effectiveness, and novel drug delivery systems like controlled and sustained systems.
The children segment accounted for the highest market share of 57.25% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the applications, the global mebendazole market is categorized as adult and children. Among these, the children segment accounted for the highest market share of 57.25% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The mebendazole market, primarily targeting children, treats parasitic infections like pinworm, roundworm, and hookworm. Its growth is fueled by cost-effectiveness, safety, and public health programs, with success driven by child-friendly packaging and rising demand.
The hospital pharmacies segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the distribution channel, the global mebendazole market is categorized as retail pharmacies, online pharmacies, and hospital pharmacies. Among these, the hospital pharmacies segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. This is attributed to collaboration between hospital pharmacies, skilled pharmacists, wide mebendazole tablet stock availability, drug counseling and dispensing services, and cost-effective medication offerings.
Asia Pacific is expected to hold the greatest share of the global mebendazole market over the forecast period.
Get more details on this report -
Asia Pacific is expected to hold the greatest share of the global mebendazole market over the forecast period. The global mebendazole market is expanding due to research and development strategies, increasing pinworm infections, and rising healthcare expenditure. India and China are driving market growth due to their large populations and improved healthcare infrastructure. Increased awareness of parasitic infections and public health initiatives also contribute to market growth. Pharmaceutical companies are developing advanced formulations to improve treatment outcomes.
North America is predicted to grow at the fastest CAGR throughout the estimated period. The mebendazole market is fueled by high awareness, advanced healthcare systems, and major pharmaceutical companies. The US is growing in North America due to R&D expenditure and is a major player in wholesale drugs and dosage construction. The market operates as a free economy, promoting transparent trade practices and limiting anti-competitive practices. Mebendazole is in high demand due to gastrointestinal parasitic diseases in vulnerable populations and pediatric healthcare due to its effectiveness and minimal side effects.
Major key players in the global mebendazole market are Takeda Pharmaceutical Company Limited, Bayer AG, Mylan N.V., GlaxoSmithKline plc, Johnson and Johnson, Amgen Inc., Bristol- Myers Squibb Company, Gilead Sciences, Inc., Roche Holding AG, AbbVie Inc., Cipla Limited, Sun Pharmaceutical Industries Ltd., and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In January 2024, Johnson & Johnson committed to extending its global product donations of VERMOX® Chewable (Mebendazole chewable 500mg tablets), its intestinal worm treatment, through 2030. The five-year extended commitment will ensure up to one billion doses of the medicine are available to treat children and women of reproductive age in endemic countries, or up to 200 million doses per year.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global mebendazole market based on the below-mentioned segments:
Global Mebendazole Market, By Dosage Form
- Chewable Tablets
- Oral Suspension
- Tablets
Global Mebendazole Market, By Applications
- Adult
- Children
Global Mebendazole Market, By Distribution Channel
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Global Mebendazole Market, By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?